Mice lacking nucleotide sugar transporter SLC35A3 exhibit lethal chondrodysplasia with vertebral anomalies and impaired glycosaminoglycan biosynthesis

SLC35A3 is considered an uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) transporter in mammals and regulates the branching of N-glycans. A missense mutation in SLC35A3 causes complex vertebral malformation (CVM) in cattle. However, the biological functions of SLC35A3 have not been fully clarified. To address these issues, we have established Slc35a3–/–mice using CRISPR/Cas9 genome editing system. The generated mutant mice were perinatal lethal and exhibited chondrodysplasia recapitulating CVM-like vertebral anomalies. During embryogenesis, Slc35a3 mRNA was expressed in the presomitic mesoderm of wild-type mice, suggesting that SLC35A3 transports UDP-GlcNAc used for the sugar modification that is essential for somite formation. In the growth plate cartilage of Slc35a3–/–embryos, extracellular space was drastically reduced, and many flat proliferative chondrocytes were reshaped. Proliferation, apoptosis and differentiation were not affected in the chondrocytes of Slc35a3–/–mice, suggesting that the chondrodysplasia phenotypes were mainly caused by the abnormal extracellular matrix quality. Because these histological abnormalities were similar to those observed in several mutant mice accompanying the impaired glycosaminoglycan (GAG) biosynthesis, GAG levels were measured in the spine and limbs of Slc35a3–/–mice using disaccharide composition analysis. Compared with control mice, the amounts of heparan sulfate, keratan sulfate, and chondroitin sulfate/dermatan sulfate, were significantly decreased in Slc35a3–/–mice. These findings suggest that SLC35A3 regulates GAG biosynthesis and the chondrodysplasia phenotypes were partially caused by the decreased GAG synthesis. Hence, Slc35a3−/− mice would be a useful model for investigating the in vivo roles of SLC35A3 and the pathological mechanisms of SLC35A3-associated diseases

Mice lacking nucleotide sugar transporter SLC35A3 exhibit lethal chondrodysplasia with vertebral anomalies and impaired glycosaminoglycan biosynthesis.

SLC35A3 is considered an uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) transporter in mammals and regulates the branching of N-glycans. A missense mutation in SLC35A3 causes complex vertebral malformation (CVM) in cattle. However, the biological functions of SLC35A3 have not been fully clarified. To address these issues, we have established Slc35a3-/-mice using CRISPR/Cas9 genome editing system. The generated mutant mice were perinatal lethal and exhibited chondrodysplasia recapitulating CVM-like vertebral anomalies. During embryogenesis, Slc35a3 mRNA was expressed in the presomitic mesoderm of wild-type mice, suggesting that SLC35A3 transports UDP-GlcNAc used for the sugar modification that is essential for somite formation. In the growth plate cartilage of Slc35a3-/-embryos, extracellular space was drastically reduced, and many flat proliferative chondrocytes were reshaped. Proliferation, apoptosis and differentiation were not affected in the chondrocytes of Slc35a3-/-mice, suggesting that the chondrodysplasia phenotypes were mainly caused by the abnormal extracellular matrix quality. Because these histological abnormalities were similar to those observed in several mutant mice accompanying the impaired glycosaminoglycan (GAG) biosynthesis, GAG levels were measured in the spine and limbs of Slc35a3-/-mice using disaccharide composition analysis. Compared with control mice, the amounts of heparan sulfate, keratan sulfate, and chondroitin sulfate/dermatan sulfate, were significantly decreased in Slc35a3-/-mice. These findings suggest that SLC35A3 regulates GAG biosynthesis and the chondrodysplasia phenotypes were partially caused by the decreased GAG synthesis. Hence, Slc35a3-/- mice would be a useful model for investigating the in vivo roles of SLC35A3 and the pathological mechanisms of SLC35A3-associated diseases

Proliferation, apoptosis, and differentiation are not affected in <i>Slc35a3</i>^{<i>−/−</i>} chondrocytes.

(A) BrdU staining of the tibia sections from the BrdU-treated embryos at E18.5. RC, round chondrocyte zone; FC, flat chondrocyte zone. (B) Frequency of BrdU-positive cells in the RC and FC zones. (C) TUNEL staining of the hypertrophic chondrocyte zone in the tibia sections at E18.5. (D) Frequency of TUNEL-positive cells in the hypertrophic chondrocyte zone. (E) HE staining and in situ hybridization (ISH) images, produced using Col2a1 and Col10a1 probes of the tibia sections at E18.5. (F) Heights of Col2a1- and Col10a1-expressing zones (upper graphs), and the relative heights of Col2a1- and Col10a1-expressing zones normalized by the total heights of the growth plate (lower graphs) in the ISH images. Data are shown as the means ± standard deviation; n = 6 (B, D) and 4 (F). Combined values from three (B, D) and two (F) independent sections were compared. Two separate areas were counted in one section (B, D, F). P values were calculated using Student’s t-test. Ctrl, control (wild-type + Slc35a1+/−); N.S., not significant. Scale bars, 200 μm (A, E) and 100 μm (C).</p

<i>Slc35a3</i> mRNA was expressed in the presomitic mesoderm during somite formation.

Whole-mount in situ hybridization images of wild-type mouse embryos at E9.25 (somite 20–22) produced using the antisense (A, B) and the sense (C) probes against Slc35a3 mRNA. Lateral side view (A), and the magnified images of the tail region (B, C). NE: neuroepithelium, PSM: presomatic mesoderm. Scale bars: 500 μm. The same results were obtained from two independent experiments.</p

HPLC profiles of the keratanase digests of GAG-peptide preparations from the spine.

The 2-aminobenzamide (2AB)-derivatives of the yielded KS disaccharides after digestion with a keratanase-II were separated using anion-exchange HPLC on an amine-bound silica PA-G column with a linear gradient of NaH2PO4 as indicated by the dashed line for analysis of KS. HLPC profiles of the spine samples of control (A) and Slc35a3–/–mice (B). The elution positions of 2AB-labeled KS disaccharide standards are indicated by numbered arrows: 1, Gal-GlcNAc(6S); 2, Gal(6S)-GlcNAc(6S). Abbreviation: KS, keratan sulfate; Gal, D-galactose; GlcNAc, N-acetyl-D-glucosamine; 6S, 6-O-sulfate. (TIF)</p

HPLC profiles of the heparinase digests of GAG-peptide preparations from the spine and limbs.

The 2-aminobenzamide (2AB)-derivatives of the yielded HS disaccharides after digestion with a mixture of heparinase-I, heparitinase-II, and heparinase-III, were separated using anion-exchange HPLC on an amine-bound silica PA-G column with a linear gradient of NaH2PO4 as indicated by the dashed line for the analysis of HS. HPLC profiles of the spine (A, B) and limb (C, D) samples of control (A, C) and Slc35a3−/− mice (B, D). The elution positions of 2AB-labeled HS disaccharide standards are indicated by numbered arrows: 1, ΔHexUA-GlcNAc; 2, ΔHexUA-GlcNAc(6S); 3, ΔHexUA-GlcN(NS); 4, ΔHexUA-GlcN(NS,6S); 5, ΔHexUA(2S)-GlcN(NS); 6, ΔHexUA(2S)-GlcN(NS,6S). Abbreviations: HS, heparan sulfate; ΔHexUA, 4,5-unsaturated hexuronic acid; GlcNAc, N-acetyl-D-glucosamine; GlcN, D-glucosamine; 2S, 2-O-sulfate; 4S, 4-O-sulfate; 6S, 6-O-sulfate; NS, 2-N-sulfate. (TIF)</p

S1 Raw images -

SLC35A3 is considered an uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) transporter in mammals and regulates the branching of N-glycans. A missense mutation in SLC35A3 causes complex vertebral malformation (CVM) in cattle. However, the biological functions of SLC35A3 have not been fully clarified. To address these issues, we have established Slc35a3–/–mice using CRISPR/Cas9 genome editing system. The generated mutant mice were perinatal lethal and exhibited chondrodysplasia recapitulating CVM-like vertebral anomalies. During embryogenesis, Slc35a3 mRNA was expressed in the presomitic mesoderm of wild-type mice, suggesting that SLC35A3 transports UDP-GlcNAc used for the sugar modification that is essential for somite formation. In the growth plate cartilage of Slc35a3–/–embryos, extracellular space was drastically reduced, and many flat proliferative chondrocytes were reshaped. Proliferation, apoptosis and differentiation were not affected in the chondrocytes of Slc35a3–/–mice, suggesting that the chondrodysplasia phenotypes were mainly caused by the abnormal extracellular matrix quality. Because these histological abnormalities were similar to those observed in several mutant mice accompanying the impaired glycosaminoglycan (GAG) biosynthesis, GAG levels were measured in the spine and limbs of Slc35a3–/–mice using disaccharide composition analysis. Compared with control mice, the amounts of heparan sulfate, keratan sulfate, and chondroitin sulfate/dermatan sulfate, were significantly decreased in Slc35a3–/–mice. These findings suggest that SLC35A3 regulates GAG biosynthesis and the chondrodysplasia phenotypes were partially caused by the decreased GAG synthesis. Hence, Slc35a3−/− mice would be a useful model for investigating the in vivo roles of SLC35A3 and the pathological mechanisms of SLC35A3-associated diseases.</div

Generation of <i>Slc35a3</i>^–/–mice using genome editing.

(A) Sequence chromatograms of the edited genomic region in exon 3 of the Slc35a3 gene. A homozygous 17-bp deletion (c.255_271del) leading to frameshift occurred in Slc35a3–/–mice. (B) Agarose gel electrophoresis image of PCR products used for genotyping. +/+: wild-type; +/−: Slc35a3+/−; −/−: Slc35a3−/−. Upper band: wild-type allele-specific PCR products; lower band: 17-bp deletion allele-specific PCR products. (C) Gross appearance of wild-type and Slc35a3−/− littermate embryos at E18.5. (D) Relative Slc35a3 mRNA expression in the limbs of wild-type (+/+) and Slc35a3–/–mice (−/−). Data are shown as means ± standard deviation (n = 4). P values were calculated using Student’s t-test. (E) Structural comparison of wild-type and mutant SLC35A3 proteins. The wild-type SLC35A3 protein consists of 327 amino acids with 10 predicted transmembrane domains, whereas the mutant protein consists of 85 SLC35A3-specific amino acids with 2 transmembrane domains and 42 mutant specific amino acids.</p